Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise

BioPharma Dive December 5, 2024
Kristin Jensen

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.

Dive Brief:

• Atlas Venture said Thursday that it’s raised $450 million for its 14th fund, through which the firm will continue to seed and grow new biotechnology companies.
• Partner Bruce Booth called the fundraising round the smoothest and most efficient he’s seen in 20 years at the firm. “Given the level of demand, we could have raised several multiples of what we set as our hard cap” of $450 million, Booth wrote in a blog post.
• Booth, Kevin Bitterman, Michael Gladstone, David Grayzel and Jason...

Today's Sponsors

Today's Sponsor